Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. (JSPR) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
jspr · stock forecast · 13 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 13 Wall Street analysts in the past 3 months
Buy
13 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$3.00
Consensus
$3.00
+541.0% upside
Low
$3.00
Median: $3 · Last Close: $0.47
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.44 | ↓ 5.00% |
1-day model range: $0.43–$0.46. Peak: $0.46 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · JSPR · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-15 | TD Cowen | Downgrade ↓ | Buy→Hold |
| 2026-05-15 | RBC Capital | Maintains | Sector Perform→Sector Perform |
| 2026-04-01 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2025-11-11 | RBC Capital | Maintains | Sector Perform→Sector Perform |
| 2025-09-22 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2025-09-22 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2025-09-22 | BTIG | Maintains | Buy→Buy |
| 2025-08-15 | UBS | Maintains | Buy→Buy |
| 2025-07-08 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2025-07-08 | Evercore ISI Group | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Jasper Therapeutics, Inc. (JSPR) stock. Of the recent 57 rating actions, 0 were upgrades and 4 were downgrades. 13 analysts currently cover JSPR.
Analyst Recommendation Trends
JSPR analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 96.7% YoY
Revenue Next Year
$0M
↓ 84.4% YoY
EPS This Year
$-1.03
EPS Next Year
$-1.22
↑ 18.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast JSPR EPS of $-1.03 for the current fiscal year, based on estimates from 4 analysts. The JSPR revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The JSPR stock forecast is supported by two independent data sources: analyst consensus ratings from 13 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus JSPR price target is $3.00 (+541.0% upside), with an analyst consensus of Buy.
The JSPR short-term stock prediction for tomorrow is $0.44 (-5.00%).
Jasper Therapeutics, Inc. trades on NASDAQ under the ticker JSPR. The JSPR stock outlook for 2027 is broadly positive, supported by a Buy consensus among 62% of covering analysts.
Frequently asked questions
JSPR forecast · 8 questionsAccording to 13 Wall Street analysts, the average 12-month JSPR price target is $3.00, with a high forecast of $3.00 and a low of $3.00. The median price target is shown in the chart above when available. This implies +541.0% potential upside from the current price of $0.47.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.